L&K Biomed’s U.S. Arm Showcases Pectus Implant at Prestigious Nuss Procedure Course in Virginia

News | 2025-10-24 14:57:42
[medi・K / HEALTH IN NEWS] Aegis Meditech, the American subsidiary of South Korean medical device maker L&K Biomed, presented its Pectus implant system at the 23rd annual NUSS Advanced Pectus Course on Jan. 22, held at Eastern Virginia Medical School.

The invitation-only event, co-hosted by Children’s Hospital of The King’s Daughters and EVMS, is widely regarded as the premier training forum for the Nuss Procedure — the minimally invasive surgical correction of pectus excavatum pioneered by Donald Nuss, M.D., who again participated this year. The three-day program combined didactic lectures, hands-on cadaveric workshops, case-based discussions, and a dedicated session on optimizing patient outcomes with the Pectus system.

Franklin Magaran, M.D., a pediatric surgeon at CHKD with more than 3,000 chest-wall deformity cases, demonstrated intraoperative use of the Pectus implant and reviewed pre- and postoperative imaging. Jamie Golden, M.D., also of CHKD, led a module on the Pectus sternal screw system during the sternal elevation portion of the curriculum.

Dr. Donald Nuss (center) poses with L&K Biomed representatives at the NUSS Advanced Pectus Course 2025 in Norfolk, Va. (Photo provided by L&K Biomed)
Dr. Donald Nuss (center) poses with L&K Biomed representatives at the NUSS Advanced Pectus Course 2025 in Norfolk, Va. (Photo provided by L&K Biomed)


“The Pectus line delivers consistent satisfaction for surgeons and patients alike,” Dr. Magaran said. “Its iterative design improvements have made it exceptionally versatile for achieving our surgical goals. This course is an ideal platform to share evidence-based techniques and product refinements with the global thoracic community.”

Aegis Meditech operated an exclusive exhibit booth throughout the conference, offering live assembly and disassembly demonstrations. Attendees — primarily thoracic surgeons from North America, Europe, and Asia — expressed particular interest in the system’s modularity and ease of sterilization.

An L&K Biomed spokesperson said the company plans to expand physician training programs domestically and abroad. “The enthusiastic response from international faculty underscores Pectus’s potential in the global market for chest-wall reconstruction,” the spokesperson added.

Sora Song / press@themedik.kr
Copyright © 2020 mediK. All rights reserved.